Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
44
BNTC Quote, Financials, Valuation and Earnings
Last price:
$10.73
Seasonality move
:
27.63%
Day range:
$10.50 - $10.95
52-week range:
$9.80 - $17.15
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.97x
Volume:
132.2K
Avg. volume:
135.4K
1-year change:
-5.13%
Market cap:
$368.3M
Revenue:
--
EPS (TTM):
-$0.93
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BNTC
Benitec Biopharma, Inc.
|
-- | -$0.42 | -100% | -- | $23.83 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.53 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835M | $0.56 | 11.9% | 36.21% | $88.87 |
|
IMNN
Imunon, Inc.
|
-- | -$1.82 | -- | -269.06% | $21.50 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BNTC
Benitec Biopharma, Inc.
|
$10.72 | $23.83 | $368.3M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$24.73 | $31.53 | $4.2B | 15.91x | $0.00 | 0% | 3.98x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$329.35 | $457.00 | $43.7B | 145.92x | $0.00 | 0% | 11.84x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$62.92 | $88.87 | $12.1B | 23.58x | $0.00 | 0% | 3.99x |
|
IMNN
Imunon, Inc.
|
$3.19 | $21.50 | $6.8M | -- | $0.00 | 0% | 16.43x |
|
SVRA
Savara, Inc.
|
$5.70 | $10.81 | $1.2B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BNTC
Benitec Biopharma, Inc.
|
0.52% | -0.204 | 0.21% | 67.49x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.896 | 5.87% | 2.84x |
|
IMNN
Imunon, Inc.
|
21.26% | 5.236 | 10.13% | 1.25x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BNTC
Benitec Biopharma, Inc.
|
-$120K | -$13.4M | -35.07% | -35.31% | -- | -$3.8M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
IMNN
Imunon, Inc.
|
-$167K | -$3.5M | -282.76% | -365% | -- | -$4.4M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
Benitec Biopharma, Inc. vs. Competitors
-
Which has Higher Returns BNTC or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Benitec Biopharma, Inc.'s net margin of 25.76%. Benitec Biopharma, Inc.'s return on equity of -35.31% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital BNTCBenitec Biopharma, Inc.-- -$0.26 $188.3M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About BNTC or ACAD?
Benitec Biopharma, Inc. has a consensus price target of $23.83, signalling upside risk potential of 122.33%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.53 which suggests that it could grow by 27.48%. Given that Benitec Biopharma, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Benitec Biopharma, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BNTCBenitec Biopharma, Inc.6 0 0 ACADACADIA Pharmaceuticals, Inc.10 5 1 -
Is BNTC or ACAD More Risky?
Benitec Biopharma, Inc. has a beta of 0.258, which suggesting that the stock is 74.182% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock BNTC or ACAD?
Benitec Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Benitec Biopharma, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BNTC or ACAD?
Benitec Biopharma, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Benitec Biopharma, Inc.'s net income of -$11.8M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Benitec Biopharma, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Benitec Biopharma, Inc. is -- versus 3.98x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BNTCBenitec Biopharma, Inc.-- -- -- -$11.8M ACADACADIA Pharmaceuticals, Inc.3.98x 15.91x $278.6M $71.8M
-
Which has Higher Returns BNTC or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Benitec Biopharma, Inc.'s net margin of 16.99%. Benitec Biopharma, Inc.'s return on equity of -35.31% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital BNTCBenitec Biopharma, Inc.-- -$0.26 $188.3M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About BNTC or ALNY?
Benitec Biopharma, Inc. has a consensus price target of $23.83, signalling upside risk potential of 122.33%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 38.76%. Given that Benitec Biopharma, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Benitec Biopharma, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BNTCBenitec Biopharma, Inc.6 0 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is BNTC or ALNY More Risky?
Benitec Biopharma, Inc. has a beta of 0.258, which suggesting that the stock is 74.182% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock BNTC or ALNY?
Benitec Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Benitec Biopharma, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BNTC or ALNY?
Benitec Biopharma, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Benitec Biopharma, Inc.'s net income of -$11.8M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Benitec Biopharma, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 145.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Benitec Biopharma, Inc. is -- versus 11.84x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BNTCBenitec Biopharma, Inc.-- -- -- -$11.8M ALNYAlnylam Pharmaceuticals, Inc.11.84x 145.92x $1.1B $186.4M
-
Which has Higher Returns BNTC or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -- compared to Benitec Biopharma, Inc.'s net margin of -3.91%. Benitec Biopharma, Inc.'s return on equity of -35.31% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital BNTCBenitec Biopharma, Inc.-- -$0.26 $188.3M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About BNTC or BMRN?
Benitec Biopharma, Inc. has a consensus price target of $23.83, signalling upside risk potential of 122.33%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 41.24%. Given that Benitec Biopharma, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Benitec Biopharma, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BNTCBenitec Biopharma, Inc.6 0 0 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is BNTC or BMRN More Risky?
Benitec Biopharma, Inc. has a beta of 0.258, which suggesting that the stock is 74.182% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock BNTC or BMRN?
Benitec Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Benitec Biopharma, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BNTC or BMRN?
Benitec Biopharma, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Benitec Biopharma, Inc.'s net income of -$11.8M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Benitec Biopharma, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 23.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Benitec Biopharma, Inc. is -- versus 3.99x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BNTCBenitec Biopharma, Inc.-- -- -- -$11.8M BMRNBioMarin Pharmaceutical, Inc.3.99x 23.58x $786.8M -$30.7M
-
Which has Higher Returns BNTC or IMNN?
Imunon, Inc. has a net margin of -- compared to Benitec Biopharma, Inc.'s net margin of --. Benitec Biopharma, Inc.'s return on equity of -35.31% beat Imunon, Inc.'s return on equity of -365%.
Company Gross Margin Earnings Per Share Invested Capital BNTCBenitec Biopharma, Inc.-- -$0.26 $188.3M IMNNImunon, Inc.-- -$1.16 $5.2M -
What do Analysts Say About BNTC or IMNN?
Benitec Biopharma, Inc. has a consensus price target of $23.83, signalling upside risk potential of 122.33%. On the other hand Imunon, Inc. has an analysts' consensus of $21.50 which suggests that it could grow by 573.98%. Given that Imunon, Inc. has higher upside potential than Benitec Biopharma, Inc., analysts believe Imunon, Inc. is more attractive than Benitec Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BNTCBenitec Biopharma, Inc.6 0 0 IMNNImunon, Inc.3 1 0 -
Is BNTC or IMNN More Risky?
Benitec Biopharma, Inc. has a beta of 0.258, which suggesting that the stock is 74.182% less volatile than S&P 500. In comparison Imunon, Inc. has a beta of 2.135, suggesting its more volatile than the S&P 500 by 113.504%.
-
Which is a Better Dividend Stock BNTC or IMNN?
Benitec Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Benitec Biopharma, Inc. pays -- of its earnings as a dividend. Imunon, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BNTC or IMNN?
Benitec Biopharma, Inc. quarterly revenues are --, which are smaller than Imunon, Inc. quarterly revenues of --. Benitec Biopharma, Inc.'s net income of -$11.8M is lower than Imunon, Inc.'s net income of -$3.4M. Notably, Benitec Biopharma, Inc.'s price-to-earnings ratio is -- while Imunon, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Benitec Biopharma, Inc. is -- versus 16.43x for Imunon, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BNTCBenitec Biopharma, Inc.-- -- -- -$11.8M IMNNImunon, Inc.16.43x -- -- -$3.4M
-
Which has Higher Returns BNTC or SVRA?
Savara, Inc. has a net margin of -- compared to Benitec Biopharma, Inc.'s net margin of --. Benitec Biopharma, Inc.'s return on equity of -35.31% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital BNTCBenitec Biopharma, Inc.-- -$0.26 $188.3M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About BNTC or SVRA?
Benitec Biopharma, Inc. has a consensus price target of $23.83, signalling upside risk potential of 122.33%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 89.69%. Given that Benitec Biopharma, Inc. has higher upside potential than Savara, Inc., analysts believe Benitec Biopharma, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BNTCBenitec Biopharma, Inc.6 0 0 SVRASavara, Inc.6 0 0 -
Is BNTC or SVRA More Risky?
Benitec Biopharma, Inc. has a beta of 0.258, which suggesting that the stock is 74.182% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock BNTC or SVRA?
Benitec Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Benitec Biopharma, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BNTC or SVRA?
Benitec Biopharma, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Benitec Biopharma, Inc.'s net income of -$11.8M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Benitec Biopharma, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Benitec Biopharma, Inc. is -- versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BNTCBenitec Biopharma, Inc.-- -- -- -$11.8M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 36x
Sell
48
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
ACLX alert for Feb 24
Arcellx, Inc. [ACLX] is up 77.43% over the past day.
Buy
65
RNG alert for Feb 24
RingCentral, Inc. [RNG] is down 12.48% over the past day.
Buy
69
SNSE alert for Feb 24
Sensei Biotherapeutics, Inc. [SNSE] is down 2.63% over the past day.
